Amicas is jockeying to pick up the pieces of an acquisition gone wrong.
Amicas is jockeying to pick up the pieces of an acquisition gone wrong. Health Systems Solutions' attempt to buy Emageon failed earlier this month when adequate financing could not be found. PACS/IT vendor Amicas announced Feb. 23 that it has entered into a definitive merger agreement to pay $1.82 per share in cash for all Emageon common stock. The total, about $39 million, is much less than the ill-fated HSS bid of $62 million, but Amicas is in a better position to complete the deal than was the previous suitor. Amicas ended 2008 with cash, cash equivalents, and marketable securities of approximately $55 million and no long-term debt. The Emageon board of directors has unanimously recommended that shareholders tender their shares in the offer. Shareholders representing approximately 18% of outstanding Emageon shares have already agreed to do so.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.